Instil Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Operating income | -$78.6M | -$73.5M | -$159.2M | -$226.5M | -$155.6M |
| Operating expenses | $78.6M | $73.5M | $159.2M | $226.5M | $155.6M |
| Cash from operations | -$36.6M | -$55.7M | -$82.0M | -$180.2M | -$122.1M |
| Capital expenditure | — | $0 | $20.7M | $84.6M | $57.8M |
| Free cash flow | — | -$55.7M | -$102.7M | -$264.8M | -$180.0M |
| Impairments | — | $4.3M | $0 | $15.8M | $0 |
| Total assets | $203.5M | $263.6M | $325.6M | $482.1M | $610.0M |
| Total liabilities | $89.7M | $94.1M | $99.8M | $118.5M | $54.8M |
Shares outstanding 6.8M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.